icon-folder.gif   Conference Reports for NATAP  
 
  17th European AIDS Conference
November 6-9
2019, Basel
Back grey_arrow_rt.gif
 
 
 
SWORD-1&-2: MAINTENANCE OR IMPROVEMENT IN RENAL FUNCTION IN PLWH THROUGH 148 WEEKS AFTER SWITCH TO THE DOLUTEGRAVIR + RILPIVIRINE 2-DRUG REGIMEN
 
 
  17th European AIDS Conference, November 6-9, 2019, Basel
Reported by Jules Levin
 
JM Llibre,1 E Voronin,2 R Rubio,3 P-M Girard,4 F Bredeek,5 J van Wyk,6 L Kahl,6 B Jones,6 L Curtis,7 B Wynne,8 M Nascimento,6 J Koteff,8 M Gartland,8 K Angelis,7 K Vandermeulen,9 K Smith8 1University Hospital Germans Trias and the Fight AIDS Foundation, Badalona, Barcelona, Spain; 2Hospital of Infectious Diseases, St Petersburg, Russia; 3Hospital Universitario 12 Octubre, UCM, Madrid, Spain; 4Saint-Antoine Hospital, AP-HP, Paris, France; 5Metropolis Medical Group, San Francisco, CA, USA; 6ViiV Healthcare, Brentford, UK; 7GlaxoSmithKline, Uxbridge, UK; 8ViiV Healthcare, Research Triangle Park, NC, USA; 9Janssen Pharmaceutica NV, Beerse, Belgium
 
link to EACS NATAP reports - 17th European AIDS Conference
November 6-9, 2019
Basel November 6-9, 2019
Basel
 
Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen Through 48 Weeks: Subgroup Analyses From the TANGO Study - (11/07/19)
 
Baseline and Emergent Genotypic and Phenotypic Results in HIV-1-Infected, Heavily Treatment-Experienced (HTE) Participants Meeting Protocol-Defined Virologic Failure (PDVF) Criteria Through Week 96 in the Fostemsavir (FTR) Phase 3 BRIGHTE Study - (11/18/19)
 
Impact of Susceptibility Scoring on Virologic Response in Heavily Treatment-Experienced Participants with HIV-1 Receiving a Fostemsavir-Based Antiretroviral Regimen: Week 96 Results from the Randomized Cohort of the Phase 3 BRIGHTE Study - (11/18/19)
 
SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN THROUGH 48 WEEKS: SUBGROUP ANALYSES FROM THE TANGO STUDY - (11/13/19)
 
Maintenance DTG/3TC Controls HIV in People With Historical 3TC Resistance "Dolutegravir and lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a pilot clinical trial (ART-PRO)" - (11/14/19)
 
Real world data of using Triumeq (dolutegravir/abacavir/lamivudine; DTG/ABC/3TC): final outcomes of the 3-year German TRIUMPH cohort show good virologic effectiveness and safety in routine clinical practice - (11/13/19)
 
Dolutegravir (DTG) Use During Pregnancy and Birth Outcomes: Data from the Antiretroviral Pregnancy Registry (APR) - (11/13/19)
 
Safety and Efficacy of Triple Therapy with Dolutegravir plus 2 NRTIs, in Treatment-Na´ve HIV-2 Infected Patients - 48 weeks results from a Phase II Study in Portugal - (11/12/19)
 
Non inferiority of dolutegravir+emtricitabine dual therapy to standard combination antiretroviral therapy in maintaining HIV suppression throughout 48 weeks: The SIMPL'HIV study - (11/12/19)
 
ASSESSMENTS OF VERY-LOW-LEVEL HIV REPLICATION FOR DOLUTEGRAVIR + LAMIVUDINE (DTG + 3TC) VS DOLUTEGRAVIR + TENOFOVIR DISOPROXIL/EMTRICITABINE (DTG + TDF/FTC) IN THE GEMINI-1&-2 STUDIES THROUGH WEEK 96 - (11/08/19)
 
Outcomes for Women in Phase 3 Trials of Long-Acting Cabotegravir + Rilpivirine: Pooled ATLAS and FLAIR Week 48 Results - (11/08/19)
 
Shorter time to treatment failure in PLHIV switched to dolutegravir plus either rilpivirine or lamivudine compared to integrase inhibitor-based triple therapy in a large Spanish cohort - VACH Doubled Failure Risk After Switch to DTG/RPV or DTG/3TC Versus Triple-INI Regimen - Mark Mascolini - (11/08/19)
 
Once-a-Month CAB/RPV Effective in Women--Fewer Adverse Events Than Men - Mark Mascolini - (11/07/19)
 
EACS 2019: ViiV Healthcare to present 17 abstracts from its portfolio addressing the diverse needs of people living with HIV - PRESS RELEASE - (11/06/19)

1126191

1126192

1126193